Lifesci Capital Estimates Upstream Bio FY2025 Earnings

Upstream Bio, Inc. (NASDAQ:UPB) – Research analysts at Lifesci Capital issued their FY2025 earnings estimates for shares of Upstream Bio in a research report issued to clients and investors on Tuesday, December 2nd. Lifesci Capital analyst K. Dellorusso expects that the company will earn ($2.55) per share for the year. Lifesci Capital currently has a “Outperform” rating and a $43.00 target price on the stock. The consensus estimate for Upstream Bio’s current full-year earnings is ($4.30) per share. Lifesci Capital also issued estimates for Upstream Bio’s Q4 2025 earnings at ($0.67) EPS.

Other research analysts have also issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a report on Wednesday, October 8th. Evercore ISI assumed coverage on Upstream Bio in a report on Tuesday, November 18th. They issued an “outperform” rating and a $40.00 target price for the company. Finally, Truist Financial initiated coverage on Upstream Bio in a report on Tuesday, October 14th. They set a “buy” rating and a $47.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $43.33.

Upstream Bio Price Performance

NASDAQ UPB opened at $27.75 on Thursday. Upstream Bio has a fifty-two week low of $5.14 and a fifty-two week high of $33.00. The stock’s 50-day moving average is $23.40 and its two-hundred day moving average is $17.16. The firm has a market cap of $1.50 billion, a P/E ratio of -14.76 and a beta of 1.83.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.15. The business had revenue of $0.68 million during the quarter, compared to analyst estimates of $0.65 million. Upstream Bio had a negative net margin of 4,366.77% and a negative return on equity of 28.71%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in UPB. Norges Bank acquired a new position in shares of Upstream Bio during the second quarter worth approximately $10,650,000. Marshall Wace LLP increased its position in Upstream Bio by 198.8% during the third quarter. Marshall Wace LLP now owns 867,999 shares of the company’s stock worth $16,327,000 after acquiring an additional 577,473 shares during the period. Integral Health Asset Management LLC acquired a new position in Upstream Bio during the 3rd quarter valued at $10,816,000. Vanguard Group Inc. raised its stake in Upstream Bio by 12.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,442,551 shares of the company’s stock valued at $45,944,000 after purchasing an additional 271,718 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Upstream Bio by 57.5% in the 2nd quarter. Geode Capital Management LLC now owns 646,635 shares of the company’s stock valued at $7,101,000 after purchasing an additional 235,958 shares during the period.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.